IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its ...

Men are more likely to be diagnosed with advanced melanoma compared with women, and have a greater risk for recurrence and mortality.

Adolescents and young adults with stage IV cancer have unique primary tumor sources and survive longer with synchronous brain metastases than older adults.

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with ...

Producing the highest accuracy, the 9-gene set produced became the basis of the final classifier. When applied to multiple ...

On December 10, 2025, NuCana announced the presentation of new clinical data at the ESMO Immuno-Oncology Congress 2025, showcasing the potential of NUC-7738 in treating PD-1 inhibitor-resistant ...

This collaboration broadens access to advanced monitoring solutions for uveal melanoma patients in the United States, helping to address the needs of a largely underserved patient population. By ...

Delcath Systems, Inc. announced the publication of a retrospective study reporting outcomes from patients with liver-dominant ...

The Oxford dictionary defines a tumour as “any abnormal swelling in or on a part of the body”. They develop in nearly any ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...